Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

Completed · Phase 4

Conditions studied: ADHD

In brief

Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted. Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response

Key facts

Study ID

NCT00663442

Run by

University of Illinois at Chicago

People needed

48

Starts

1999-12-01

Expected to finish

2004-11-01

Last updated by the study team

2008-04-22

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 6-17 DSM IV criteria for ADHD Parents willing to complete measures

You may not qualify if…

• Mental retardation psychoses seizure disorder

Where it is running

• HALP Clinic, University of Illinois at CHicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.